Real-World Treatment of Schizophrenia in Adults With a 22q11.2 Microdeletion: Traitement dans le monde réel de la schizophrénie chez des adultes atteints du syndrome de microdélétion 22q11.2
Lily Van,Tracy Heung,Nikolai Gil D. Reyes,Erik Boot,Eva W. C. Chow,Maria Corral,Anne S. Bassett
DOI: https://doi.org/10.1177/07067437241293983
2024-12-08
The Canadian Journal of Psychiatry
Abstract:The Canadian Journal of Psychiatry, Ahead of Print. ObjectiveOne in every 4 individuals born with a 22q11.2 microdeletion will develop schizophrenia. Thirty years of clinical genetic testing capability have enabled detection of this major molecular susceptibility for psychotic illness. However, there is limited literature on the treatment of schizophrenia in individuals with a 22q11.2 microdeletion, particularly regarding the issue of treatment resistance.MethodsFrom a large, well-characterized adult cohort with a typical 22q11.2 microdeletion followed for up to 25 years at a specialty clinic, we studied all 107 adults (49 females, 45.8%) meeting the criteria for schizophrenia or schizoaffective disorder. We performed a comprehensive review of lifetime (1,801 patient-years) psychiatric records to determine treatments used and the prevalence of treatment-resistant schizophrenia (TRS). We used Clinical Global Impression–Improvement (CGI-I) scores to compare within-individual responses to clozapine and nonclozapine antipsychotics. For a subgroup with contemporary data (n = 88, 82.2%), we examined antipsychotics and dosage at the last follow-up.ResultsLifetime treatments involved on average 4 different antipsychotic medications per individual. Sixty-three (58.9%) individuals met the study criteria for TRS, a significantly greater proportion than for a community-based comparison (42.9%; χ2 = 10.38, df = 1, p < 0.01). The non-TRS group was enriched for individuals with genetic diagnosis before schizophrenia diagnosis. Within-person treatment response in TRS was significantly better for clozapine than for nonclozapine antipsychotics (p < 0.0001). At the last follow-up, clozapine was the most common antipsychotic prescribed, followed by olanzapine, risperidone, and paliperidone. Total antipsychotic chlorpromazine equivalent dosages were in typical clinical ranges (median: 450 mg; interquartile range: 300, 750 mg).ConclusionThe results for this large sample indicate that patients with 22q11.2 microdeletion have an increased propensity to treatment resistance. The findings provide evidence about how genetic diagnosis can inform clinical psychiatric management and could help reduce treatment delays. Further research is needed to shed light on the pathophysiology of antipsychotic response and on strategies to optimize outcomes.Plain Language Summary TitleReal-world treatment of schizophrenia in adults with a 22q11.2 microdeletionPlain Language SummaryThere is little uptake of clinical genetic testing in psychiatry. A major question has been whether genetics can provide information that is relevant for the psychiatrist's clinical treatment decisions. The most common of the rare genetic changes that are associated with increased risk for schizophrenia (SZ) is a deletion on the long arm of chromosome 22 (22q11.2 microdeletion). This study examined real-world clinical data amassed for 107 individuals with SZ and microdeletion 22q11.2. Using conservative criteria and the lifetime treatment history, the research team compared two groups, with and without treatment resistance. Nearly 60% of individuals with SZ and 22q11.2 microdeletion had treatment resistance, a significantly greater proportion than the comparison sample, and greater than usual expectations of about 30%. The subgroup with treatment resistance had been tried on an average of 5 antipsychotics, significantly more than the no treatment resistance group. Dosages for the many antipsychotics used appeared to be in the usually reported range for SZ. This suggests that effectiveness and tolerability of the medications for individuals with 22q11.2 microdeletion may be comparable to those for others with SZ. Clozapine, the antipsychotic recommended for individuals with treatment-resistant SZ, showed greater effectiveness than other antipsychotics within individuals, although average dosage was in the low end of the range typically used. This study shows evidence of a connection between genetic variation and clinical intervention in SZ. The results add to those of recent studies suggesting that individuals with a 22q11.2 microdeletion and similar clinically relevant genetic changes are hidden within treatment-resistant SZ populations. The findings support the clinical utility of molecular diagnosis for SZ, and the potential value of this genetic model for studying SZ and its treatment.
psychiatry